Filter News

The Most Affordable CAR-T Biotech Stock Among Its Rivals Right Now

Published: Dec 14, 2017

Juno Therapeuticsis now the "cheapest" player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rivalbluebird bio.

Both are working on CAR-T therapies in which a patient's immune cells are extracted, taught to fight cancer and then reintroduced to the body. Juno and Bluebird each had strong data during the American Society of Hematology conference in Atlanta.